EarningsQ2 2026 Earnings Report
MX:ZLABN Q2 2026 EPS Results
Actual EPS-$9.09
Consensus EPS-$12.34
Beat/MissBeat by +$3.25
One Year Ago EPS-$6.73
MX:ZLABN Q2 2026 Revenue Results
Actual Revenue$1.94B
Expected Revenue$1.89B
Beat/MissBeat by +$47.64M
YoY Revenue Growth-3.52%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
MX:ZLABN Upcoming Earnings
Zai Lab's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ZLABN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple near-term and medium-term positive catalysts: sequential revenue growth (11% QoQ to $105.8M), a commercially profitable business, a strong cash balance ($717.5M), rapid advancement of Zoci into global registrational trials with notable efficacy signals (38.2% ORR vs ~18% comparator in neuroendocrine carcinoma), and a busy pipeline with several upcoming data milestones (ESMO presentation, ZL-1503 healthy volunteer data H2 2026, ZL-6201 initial data H1 2027, ZL-1311 IND by year-end). Management also highlighted disciplined spending and productivity efforts. Counterbalancing these positives are supply constraints, near-term revenue timing issues related to NRDL and formulation transitions, increasing competition in the IL-13/IL-31 AD space, clinical safety/combination risks, and some ambiguity around the timing of profitability and key readouts. Overall, the positives — particularly pipeline momentum, commercial profitability, and cash runway — outweigh the operational and timing uncertainties.Company Guidance
Sequential Revenue Growth and Commercial Profitability
Net product revenue grew 11% sequentially to $105.8 million in Q2 2026, and the company stated its commercial business remained commercially profitable.
Strong Cash Position
Ended the quarter with $717.5 million in cash, providing financial flexibility to continue investing in high-value global programs.
Rapid Advancement of Zoci and Multiple Registrational Programs
Zoci advanced from IND to global pivotal trials in less than 2 years. The company expects 3 registrational programs in small cell lung cancer and neuroendocrine carcinoma by year-end, a global Phase III (second-line+) expected to complete enrollment in H1 2027, a U.S. accelerated approval submission expected later in 2027, and potential approval anticipated in 2028.
Compelling Zoci Efficacy Signals
In extrapulmonary neuroendocrine carcinomas Zoci demonstrated a confirmed ORR of 38.2% versus roughly 18% seen with currently used regimens (an improvement of ~20 percentage points; >2x the comparator rate). Company also reports strong responses and control of brain metastases in heavily pretreated patients.
ZL-1503 Advancement and Potential Differentiation
ZL-1503 (IL-13L–IL-31 bispecific with YTE Fc modification) is in the clinic. First-in-human healthy volunteer data (PK/PD, biomarker and immunogenicity) will be presented in H2 2026; multiple ascending dose data in atopic dermatitis (AD) expected at a major medical conference in 2027. The program targets robust skin clearance, rapid pruritus reduction and longer dosing intervals.
Commercial Brand Momentum
VYVGART volumes grew double-digits sequentially, XACDURO demand remains strong despite supply constraints, and KarXT's launch is described as 'off to an excellent start.' Management expects these brands (plus potential NRDL inclusion and new product launches) to support a return to meaningful year-over-year growth in 2027 and a potential first U.S. product launch in 2028.
Broad Pipeline and Near-Term Milestones
Multiple programs progressing: ZL-6201 (LRRC15 ADC) enrolling with initial data expected H1 2027; ZL-1311 IND planned by year-end 2026; collaborations with Amgen and Boehringer Ingelheim for Zoci combination studies; planned presentation of ~60-patient combination dataset at ESMO (Oct 2026) with median follow-up ~8–9 months.
Disciplined Investment and Operational Efficiency
Management emphasized disciplined capital allocation, prioritizing highest-value programs, streamlining the organization and deploying AI across clinical, regulatory, commercial and corporate functions. Operating expenses expected to remain broadly stable for the remainder of the year.
MX:ZLABN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed